BMY +5% on phase-2 Opdivo date in NSCLC: http://uk.reuters.com/article/2014/10/30/us-bristol-myers-cancer-study-idUKKBN0IJ1KT20141030 http://news.bms.com/press-release/rd-news/phase-2-objective-response-rate-and-survival-data-opdivo-nivolumab-heavily-pre&t=635502569908691356